Essais de phase 2
Des essais de taille moyenne chez l'humain ont mesuré la dose et l'effet. Ce n'est pas un médicament homologué.
Cette page est une ébauche
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
Quelle est la solidité des preuves
Jusqu'où il a grimpé
Chaque médicament gravit la même échelle. La plupart des composés n'atteignent jamais le sommet, et la position d'un composé indique la solidité de ses allégations.
- Médicament autorisé
Une autorité de réglementation a examiné les essais et l'a autorisé pour un usage précis.
- Phase 3
Grands essais randomisés, souvent des milliers de personnes, contre placebo ou traitement de référence.
- Phase 2: Eloralintide
Essais de taille moyenne qui mesurent l'effet en fonction de la dose chez des personnes atteintes de la maladie.
- Phase 1 et premières études chez l'humain
Premières études chez l'humain : innocuité et manière dont l'organisme le traite.
- Cellules et animaux
Travaux en laboratoire et sur animaux. Un résultat chez l'animal n'est pas un résultat chez l'humain.
- 10
- articles sur PubMed
- 7
- dont chez l'humain
- 3
- essais randomisés
- 6
- revues
Un nombre indique la quantité de publications, et non ce qu'elles ont trouvé. Compté sur PubMed : 2026-11-16
Manipulation et reconstitution
De la poudre à un échantillon mesuré
Les mêmes quatre étapes pour tout flacon lyophilisé. Manipulation en laboratoire, et non utilisation chez une personne.
1. Lire le flacon
L'étiquette indique la masse de peptide contenue dans le flacon, en milligrammes. Ce nombre est le point de départ de chaque calcul.
2. Ajouter le diluant
Un volume mesuré de diluant est versé lentement, le long de la paroi du verre. Faites tourner doucement ; secouer peut endommager un peptide.
3. Calculer la concentration
La concentration est la masse divisée par le volume : 10 mg dans 2 mL donnent 5 mg par mL.
4. Mesurer l'échantillon
Le volume est la masse souhaitée divisée par la concentration. Sur une seringue U-100, 1 mL correspond à 100 unités.
Le calculateur ci-dessous effectue le calcul et montre son raisonnement.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Eloralintide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Eloralintide; no amount here is a recommendation.
Eloralintide: sur PubMed
What PubMed held for Eloralintide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 10
- papers
- 7
- in humans
- 3
- clinical trials
- 3
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Randomized trialBriere DA, Qu H, Lansu K, et al. Molecular metabolism, 2025. PMID 41109426
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Randomized trialBillings LK, Hsia S, Bays H, et al. Lancet (London, England), 2025. PMID 41207310
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Randomized trialBhattachar S, Tham LS, Tidemann-Miller B, et al. Diabetes, obesity & metabolism, 2026. PMID 41559929
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis
ReviewKamrul-Hasan ABM, Khalil I, Mahajan K, et al. Endocrinology, diabetes & metabolism, 2026. PMID 42175595
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
ReviewBailey CJ, Flatt PR, Conlon JM Peptides, 2026. PMID 41747885
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
ReviewPanou T, Gouveri E, Popovic DS, et al. Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. PMID 42803913
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials
ReviewAlhazmi A, le Roux CW Diabetes, obesity & metabolism, 2026. PMID 42452898
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
ReviewFischer SL, Borner T Pharmacological research, 2026. PMID 42586227
Search used: ("Eloralintide"[tiab]). Run it on PubMed
Liens de recherche
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Eloralintide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.